Mitiglinide
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| Trade names | Glufast |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
By mouth (tablets) |
| ATC code | A10BX08 (WHO) |
| Identifiers | |
|
|
| CAS Number | 145375-43-5  |
| PubChem (CID) | 121891 |
| DrugBank | DB01252  |
| ChemSpider | 108739 |
| UNII | D86I0XLB13 |
| KEGG | D01854 |
| ChEMBL | CHEMBL471498 |
| Chemical and physical data | |
| Formula | C19H25NO3 |
| Molar mass | 315.41 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (what is this?) (verify) |
|
Mitiglinide (INN,[1] trade name Glufast) is a drug for the treatment of type 2 diabetes.[2]
Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.
Pharmacology[edit]
Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium KATP channels in pancreatic β cells.
Dosage[edit]
Mitiglinide is delivered in tablet form.
References[edit]
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 40" (PDF). World Health Organization. p. 187. Retrieved 10 November 2016.
- ^ Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opin Pharmacother. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455.
External links[edit]
- Elixir Pharmaceuticals — website of the U.S. rights holder for mitiglinide.
